Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans.

Tan, Bee K, Chen, Jing, Hu, Jiamiao, Amar, Omar, Mattu, Harman S, Ramanjaneya, Manjunath, Patel, Vanlata, Lehnert, Hendrik and Randeva, Harpal S (2014) Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans. Clinical endocrinology, 81 (6). pp. 841-6. ISSN 1365-2265. This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their HEFT Athens login IDs

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/cen.12438

Abstract

OBJECTIVE

Adipolin/CTRP12 is a novel adipokine with anti-inflammatory and glucose-lowering properties in rodents. We sought to investigate the effects of metformin treatment (850 mg twice daily for 6 months) and a 2 h 75 g oral glucose tolerance test (OGTT) on serum adipolin concentrations in humans.

DESIGN

Cross-sectional study [PCOS (n = 83) and control (n = 39) subjects]. Serum adipolin was measured by ELISA. Metformin treatment (850 mg twice daily for 6 months) was offered to all women with PCOS, 34 women participated but 21 women completed 6 months of metformin therapy. Reasons for subjects not completing the study were nausea and gastrointestinal side effects (n = 4), pregnancies (n = 5), noncompliance (n = 2) and loss of contact (n = 2).

RESULTS

Metformin treatment (850 mg twice daily for 6 months) substantially increased serum adipolin concentrations (P < 0·05) in women with polycystic ovary syndrome (PCOS), a pro-inflammatory state associated with obesity, diabetes, dyslipidaemia and atherosclerosis. Furthermore, changes in waist-hip ratio, glucose, triglycerides, CRP and carotid intima media thickness showed significant negative associations with changes in adipolin levels (P < 0·05, P < 0·01); in multiple regression analyses, only changes in glucose were predictive of changes in adipolin levels (β = -0·570, P = 0·009). Serum adipolin decreased significantly in response to the OGTT in PCOS and control subjects at 90 min (P < 0·05) and 120 min (P < 0·01).

CONCLUSIONS

Adipolin and/or novel pharmacologic agents that increase adipolin's circulating concentrations might constitute a novel approach in the treatment of insulin resistant states.

Item Type: Article
Additional Information: This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their HEFT Athens login IDs
Subjects: WK Endocrine system. Endocrinology
Divisions: Womens and Childrens > Gynaecology
Womens and Childrens > Obstetrics
Related URLs:
Depositing User: Mrs Caroline Tranter
Date Deposited: 31 May 2015 07:49
Last Modified: 31 May 2015 07:49
URI: http://www.repository.uhblibrary.co.uk/id/eprint/954

Actions (login required)

View Item View Item